Ad hoc: Biofrontera AG: Biofrontera AG successfully completes capital increase
(Thomson Reuters ONE) - Biofrontera AG / Capital increase / Ad hoc: Biofrontera AG successfully completes capital increase Ad hoc announcement according to §15 WpHG processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------Leverkusen, Germany, September 25, 2009 - Biofrontera has announcedon June 24, 2009, the decision to use its authorized capital for acapital increase. Today the capital raise was completed with thelisting in the commercial register.Biofrontera AG's base capital as of today is EUR 7,595,486.00.Included in this number are all shares that were provided in theconversion of the 8% convertible bond 2005/2010 in August 2009.The new capital of more than 2,000,000.00 EUR will be used for theoperative development of Biofrontera. Essential short-term goals arethe market introduction of the medical cosmetic product Belixos® inthe fall 2009 and the completion of the phase III clinicaldevelopment of BF-200 ALA for the treatment of actinic keratosis.Furthermore, the strengthened financial basis forms an essentialrequirement for successful negotiations with future distributionpartners.Prior to the financing the voluntary offer to the holders of the 8%convertible bond 2005/2010 was closed with a very good result,leading to a significant reduction of the company's debt. The meetingof the bond holders had before decided to increase the maturity ofthe bond until July 02, 2012, and to waive the interest payments forthree years.The successful capital increase represents an important step in thefinancial stabilization of Biofrontera group, which is reflected bythe recent positive reaction of the capital market.Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen, GermanyISIN: DE0006046113, WKN: 604611Contact:Anke zur MühlenBiofrontera AGTel.: +49 (0214) 87 63 222Fax.: +49 (0214) 87 63 290E-mail: a.zurmuehlen(at)biofrontera.com --- End of Message ---Biofrontera AGHemmelrather Weg 201 Leverkusen GermanyWKN: 604611; ISIN: DE0006046113; Listed: Freiverkehr in Börse Berlin, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Open Market (Freiverkehr) in Frankfurter Wertpapierbörse, Regulierter Markt in Börse Düsseldorf;
Datum: 25.09.2009 - 14:26 Uhr
Sprache: Deutsch
News-ID 6247
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 243 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Ad hoc: Biofrontera AG: Biofrontera AG successfully completes capital increase"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
